The core physical difference, in plain terms
IMRT, or intensity-modulated radiotherapy, delivers high-energy X-rays. A linear accelerator rotates around the patient while multileaf collimators reshape the beam into many small segments, so the dose distribution is sculpted to the target from several directions. The X-ray beam does not stop at the tumour; it continues through the body, so entrance and exit doses exist even when they are kept low.
Proton therapy uses protons, accelerated in a cyclotron or synchrotron and shaped by magnets and apertures. Protons deposit most of their energy near the end of their range, a feature described as the Bragg peak, and then stop. Beyond that depth there is little or no dose. That is the physical basis for the interest in protons: the potential to reduce dose to tissue beyond the target and, depending on the plan, to tissue in front of it.
Neither technique is inherently better for every patient. The dose distribution that matters is the one calculated for a specific tumour volume, a specific set of organs at risk and a specific patient's anatomy. A proton plan that is poorly chosen can be worse than a well-planned IMRT plan, and an IMRT plan can be entirely appropriate when the target is far from sensitive structures.
What the difference may mean for dose to healthy tissue
The clinical argument for protons rests on reducing radiation dose to normal tissue, particularly in situations where the target lies close to critical structures or where a patient's previous treatment limits further dose. Published reviews and trial protocols describe this rationale for tumours near the brain, skull base, spine, eye, head and neck, and for some paediatric cancers where reducing dose to growing tissue is a priority.
That rationale is not the same as proof of better outcomes for every cancer. The evidence base comparing proton therapy with IMRT is uneven across tumour types. For some sites, randomised or prospective comparative data exist; for others, the comparison rests on dosimetric studies and observational series. Dosimetric advantage means the plan delivers less dose to a named organ; it does not automatically translate into fewer side effects, better tumour control or longer survival.
This is the question to put to the radiation oncologist directly: for this tumour, at this stage, with these nearby structures, what does each technique do to the dose received by the organs at risk, and what is the evidence that this difference matters for outcomes rather than only for dose statistics? A useful answer names the specific structures and the specific evidence, not a general claim that one machine is more advanced.
Practical differences a patient will notice
Both treatments are delivered as outpatient courses of daily fractions over several weeks, with the exact number of fractions set by the prescription. The number of visits is a clinical decision, not a fixed feature of either technique, so ask the treating team what schedule is proposed and why.
The experience during treatment is broadly similar: positioning, immobilisation, imaging before each fraction and a short beam-on time. Proton sessions can involve additional setup because the beam is shaped and verified for each field, and some centres use specific immobilisation devices. Whether that changes the daily routine for a particular patient is a question for the treating department.
Planning differs. Both require a planning CT in the treatment position, and both may use MRI or PET information to define the target. Proton planning adds the need to model how protons slow down in tissue, because small changes in density, such as air cavities or changes in anatomy during treatment, can shift where the beam stops. That is why proton centres often place particular emphasis on verification imaging and on planning margins. IMRT planning also depends on accurate target definition and on accounting for movement, but the physical behaviour of X-rays makes the dose distribution less sensitive to some of these changes.
Neither technique removes the need for careful target definition, and neither is a substitute for surgery or systemic treatment when those are indicated. Radiotherapy is usually one part of a combined plan.
Questions that decide whether the comparison is relevant
Before comparing machines, establish whether radiotherapy is the right treatment at all for the current situation, and whether it is being considered alone or alongside surgery, chemotherapy or another systemic therapy. The answers change what the radiotherapy plan must achieve.
Then ask which technique the treating centre would actually propose and why. A useful discussion covers the target volume, the organs at risk and their tolerance doses, any previous radiotherapy, the patient's age and general health, and whether the tumour moves with breathing or with filling of nearby organs. Proton therapy is not automatically indicated because it is available; guidelines generally describe it as an option in defined situations rather than a default.
Ask also about the evidence for the specific tumour type. For some cancers, comparative trials are ongoing or have reported; for others, the case for protons rests on reducing dose to structures such as the optic pathway, brainstem, spinal cord or salivary glands, where the clinical benefit is plausible but the strength of evidence varies. A clinician should be able to explain the uncertainty honestly, including what is not yet known.
Finally, ask what would change if the plan were delivered with the other technique. If the answer is that the dose to critical structures would be similar, the choice may come down to availability, cost and practical arrangements rather than a clinical advantage.
Availability and planning in China: what to confirm
Proton therapy is not available at every radiotherapy centre, and the equipment, planning software and clinical experience differ between centres. Whether a particular hospital in China offers proton therapy for a specific tumour type, and whether its team has treated that diagnosis, are questions to confirm with the hospital rather than assume from a general listing.
The same applies to IMRT, which is more widely available but still depends on the centre's planning capability and quality assurance. Ask how the centre verifies treatment delivery, how it manages set-up uncertainty and what imaging it uses during the course.
For an international patient, the practical sequence is usually: the hospital reviews the diagnosis, imaging and pathology; the radiation oncologist decides whether radiotherapy is indicated and which technique is proposed; the hospital then confirms whether it can deliver that plan and what the schedule involves. A records-based opinion can help clarify whether the question is worth pursuing, but it does not replace the treating team's planning assessment or guarantee that a particular technique will be offered.
Cost is a separate question. Proton therapy and IMRT are different services with different resource requirements, and the fee structure depends on the hospital and the plan. Ask the named hospital for a written quote that states what the radiotherapy course includes, rather than assuming a relationship between the two techniques' prices.
What to prepare before asking for a comparison
A useful comparison starts with a complete record set: the pathology report, imaging in a readable format, operative notes if surgery has occurred, previous radiotherapy records with dose details, and a clear statement of the current question. The treating radiation oncologist needs the original images, not only a summary report, to assess dose to organs at risk.
Write down the specific structures the team has identified as critical and ask what dose each technique would deliver to them. Ask whether the tumour moves and how that movement is managed. Ask what the evidence is for the tumour type and what the alternatives are, including no radiotherapy or a different schedule.
If you are considering care in China, an initial enquiry can review whether the records are sufficient to frame the question and which hospital route is relevant. That enquiry is free and does not commit you to a proxy consultation, which is optional. The hospital decides whether it can offer treatment and which technique it recommends; no coordination service can make that clinical judgement.
Sources & scope of this guide
References and official service information relevant to this guide.
- radiotherapy
- Related treatment reference
- External Beam Radiation Therapy for Cancer - NCI
- Radiation Therapy for Cancer - NCI
- Radiation Therapy Side Effects - NCI
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
